A study on the dynamics of temporary HIV treatment to assess the controversial outcomes of clinical trials: An in-silico approach

It is still unclear under which conditions temporary combined antiretroviral therapy (cART) results in a prolonged remission after interruption. Clinical trials have contradicting reposts about the effect of cART during primary HIV infection on the disease progression. Here we propose that the apparent contradiction is due the presence of a window of opportunity for cART treatment observed in the in silico studies. We study non-linear correlations in the HIV dynamics over time using information theory. This approach requires a large dataset of CD4+ T lymphocytes and viral load concentrations over time. Since it is unfeasible to collect the required amount of data in clinical trials we use C-ImmSim, a clinically validated in silico model of the HIV infection, to simulate the HIV infection and temporary cART in 500 virtual patients for a period of 6 years post infection in time steps of 8 hours. We validate the results of our model with two published clinical trials of temporary cART in acute infection and analyse the impact of cART on the immune response. Our quantitative analysis predicts a “window of opportunity” of about ten months after the acute phase during which a temporary cART has significantly longer-lasting beneficial effects on the immune system as compared to treatment during the chronic phase. This window may help to explain the controversial outcomes of clinical trials that differ by the starting time and duration of the short-term course cART and provides a critical insight to develop appropriate protocols for future clinical trials.

[1]  Lei Wang,et al.  A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. , 2006, The Journal of infectious diseases.

[2]  Steve Kaye,et al.  Short-course antiretroviral therapy in primary HIV infection. , 2013, The New England journal of medicine.

[3]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[4]  N. Pantazis,et al.  The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment , 2016, AIDS.

[5]  Peter M. A. Sloot,et al.  Cellular Automata Model of Drug Therapy for HIV Infection , 2002, ACRI.

[6]  R. M. Zorzenon dos Santos,et al.  Dynamics of HIV infection: a cellular automata approach. , 2001, Physical review letters.

[7]  F Castiglione,et al.  Design and implementation of an immune system simulator , 2001, Comput. Biol. Medicine.

[8]  S. Little,et al.  Treatment of acute HIV-1 infection: are we getting there? , 2008, Current opinion in HIV and AIDS.

[9]  Todd M. Allen,et al.  Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. , 2006, The Journal of infectious diseases.

[10]  H. Schuitemaker,et al.  No Treatment versus 24 or 60 Weeks of Antiretroviral Treatment during Primary HIV Infection: The Randomized Primo-SHM Trial , 2012, PLoS medicine.

[11]  Massimo Bernaschi,et al.  Optimization of HAART with genetic algorithms and agent-based models of HIV infection , 2007, Bioinform..

[12]  H. Hatano,et al.  Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. , 2013, The Journal of infectious diseases.

[13]  Sarah B. Laskey,et al.  Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure , 2013, Cell.

[14]  E. Rosenberg,et al.  Limited Durability of Viral Control following Treated Acute HIV Infection , 2004, PLoS medicine.

[15]  P. Vanhems,et al.  The effect of antiretroviral treatment of different durations in primary HIV infection , 2008, AIDS.

[16]  Rick Quax,et al.  The diminishing role of hubs in dynamical processes on complex networks , 2011, Journal of The Royal Society Interface.

[17]  Alan S. Perelson,et al.  Mathematical Analysis of HIV-1 Dynamics in Vivo , 1999, SIAM Rev..

[18]  P. Paci,et al.  Timely HAART initiation may pave the way for a better viral control , 2011, BMC infectious diseases.

[19]  J. Pearl.  Causality: Models, Reasoning and Inference , 2000 .

[20]  Drona Kandhai,et al.  Information dissipation as an early-warning signal for the Lehman Brothers collapse in financial time series , 2013, Scientific Reports.

[21]  C. Rouzioux,et al.  Rapid CD4+ Cell Decrease After Transient cART Initiated During Primary HIV Infection (ANRS PRIMO and SEROCO Cohorts) , 2008, Journal of acquired immune deficiency syndromes.

[22]  P. Sloot,et al.  UvA-DARE ( Digital Academic Repository ) HIV reservoirs and immune surveillance evasion cause the failure of structured treatment interruptions : a computational study , 2012 .

[23]  Hee-Dae Kwon,et al.  Optimal treatment strategies derived from a HIV model with drug-resistant mutants , 2007, Appl. Math. Comput..

[24]  Thomas M. Cover,et al.  Elements of Information Theory , 2005 .

[25]  Richard H Middleton,et al.  Modeling the three stages in HIV infection. , 2013, Journal of theoretical biology.

[26]  Peter M. A. Sloot,et al.  Towards understanding the behavior of physical systems using information theory , 2013 .

[27]  M. Donoghoe.  The HIV cascade of care in Georgia: implications for countries in Eastern Europe and Central Asia (EECA) , 2015, HIV medicine.

[28]  Massimo Bernaschi,et al.  HIV-1 Strategies of Immune Evasion , 2005 .

[29]  M. Prins,et al.  Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection. , 2010, AIDS research and human retroviruses.

[30]  Sigall K. Bell,et al.  Clinical management of acute HIV infection: best practice remains unknown. , 2010, The Journal of infectious diseases.

[31]  Mikhail Prokopenko,et al.  Differentiating information transfer and causal effect , 2008, 0812.4373.

[32]  Paul J. Birrell,et al.  Prospects of elimination of HIV with test-and-treat strategy , 2013, Proceedings of the National Academy of Sciences.

[33]  J. Lundgren,et al.  Why START? Reflections that led to the conduct of this large long‐term strategic HIV trial , 2015, HIV medicine.

[34]  Massimo Bernaschi,et al.  Mutation, fitness, viral diversity, and predictive markers of disease progression in a computational model of HIV type 1 infection. , 2004, AIDS research and human retroviruses.

[35]  Michael J. Rausch,et al.  Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort , 2009, European journal of medical research.

[36]  B. Haynes,et al.  Acute HIV-1 Infection. , 2011, The New England journal of medicine.

[37]  N. Pantazis,et al.  Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort , 2007, AIDS.

[38]  R. Salamon,et al.  Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course , 2017, The Journal of antimicrobial chemotherapy.

[39]  Xiaopeng Zhao,et al.  Evolutionary game theoretic strategy for optimal drug delivery to influence selection pressure in treatment of HIV-1 , 2011, Journal of Mathematical Biology.

[40]  J. Kinney,et al.  Equitability, mutual information, and the maximal information coefficient , 2013, Proceedings of the National Academy of Sciences.

[41]  Marios M. Hadjiandreou,et al.  Towards a long-term model construction for the dynamic simulation of HIV infection. , 2007, Mathematical biosciences and engineering : MBE.

[42]  E. Nadaraya.  On Estimating Regression , 1964 .

[43]  C. Morrison,et al.  Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection , 2016, Journal of acquired immune deficiency syndromes.

[44]  Simon Wain-Hobson.  Virus Dynamics: Mathematical Principles of Immunology and Virology , 2001, Nature Medicine.